Prophylactic Cranial Irradiation reduces brain metastases and improves overall survival in high-risk metastatic non-small cell lung cancer patients: a randomized phase II study (PRoT-BM trial).

[1]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[2]  Chunli Wu,et al.  Meta-analysis of prophylactic cranial irradiation or not in treatment of extensive-stage small-cell lung cancer: The dilemma remains. , 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[3]  M. Bernstein,et al.  Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases , 2019, Advances in radiation oncology.

[4]  A. Addeo,et al.  Prophylactic cranial irradiation in extensive disease small cell lung cancer: An endless debate. , 2019, Critical reviews in oncology/hematology.

[5]  O. Arrieta,et al.  National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version. , 2019, Salud publica de Mexico.

[6]  F. Bray,et al.  The descriptive epidemiology of lung cancer and tobacco control: a global overview 2018. , 2019, Salud publica de Mexico.

[7]  J. Salas,et al.  [Needs in coverage and care for lung cancer in Mexico]. , 2019, Salud publica de Mexico.

[8]  O. Arrieta,et al.  Access to lung cancer therapy in the Mexican population: opportunities for reducing inequity within the health system. , 2019, Salud publica de Mexico.

[9]  H. Choy,et al.  Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. , 2019, JAMA oncology.

[10]  O. Arrieta,et al.  Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients , 2019, Clinical and Translational Oncology.

[11]  Yinying Wu,et al.  A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC , 2019, Pathology & Oncology Research.

[12]  Liming Huang,et al.  Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis , 2019, BMC Cancer.

[13]  A. Dingemans,et al.  Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment , 2018, Front. Oncol..

[14]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[15]  Elizabeth Gourd.  Alectinib shows CNS efficacy in ALK-positive NSCLC. , 2018, The Lancet. Oncology.

[16]  H. Groen,et al.  Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Ahn,et al.  CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. de Ruysscher,et al.  The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation , 2018, Front. Oncol..

[19]  O. Arrieta,et al.  Factors associated with long-term survival in central nervous system metastases , 2018, Journal of Neuro-Oncology.

[20]  J. Tonn,et al.  Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion , 2018, ESMO Open.

[21]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[22]  J. Contessa,et al.  Lung Cancer Brain Metastases , 2015, Cancer journal.

[23]  L. Wilson,et al.  Prophylactic Cranial Irradiation for Patients With Locally Advanced Non-Small-Cell Lung Cancer at High Risk for Brain Metastases. , 2015, Clinical lung cancer.

[24]  D. Costa,et al.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. , 2015, Lung cancer.

[25]  L. Souhami,et al.  The Management of Brain Metastases in Non-Small Cell Lung Cancer , 2014, Front. Oncol..

[26]  A. Hackshaw,et al.  Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases , 2014, Journal of the National Cancer Institute.

[27]  P. Brown,et al.  Prophylactic cranial irradiation: recent outcomes and innovations. , 2014, CNS oncology.

[28]  C. Villarreal-Garza,et al.  Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study , 2013, BMC Cancer.

[29]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[30]  C. Villarreal-Garza,et al.  Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation , 2011, Radiation oncology.

[31]  H. Choy,et al.  Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Avilés-Salas,et al.  Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis , 2009, BMC Cancer.

[33]  V. Budach,et al.  Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Dalphin,et al.  Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. , 2004, Lung cancer.

[35]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[36]  J. Cooper,et al.  Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. , 1991, International journal of radiation oncology, biology, physics.

[37]  D. Booser,et al.  Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer , 1984, Journal of Neuro-Oncology.

[38]  Z. Petrovich,et al.  Cranial irradiation in cancer of the lung of all cell types. , 1981, JAMA.

[39]  O. Arrieta,et al.  Molecular detection and prognostic value of epithelial markers mRNA expression in peripheral blood of advanced non-small cell lung cancer patients. , 2014, Cancer biomarkers : section A of Disease markers.